Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
|Jiangsu Simcere Pharmaceutical R&D Co., Ltd. Patent applications|
|Patent application number||Title||Published|
|20140011856||SALT FORM OF TYROSINE KINASE INHIBITOR - Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments.||01-09-2014|
|20120231011||ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY - The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.||09-13-2012|
|20110003873||PHARMACEUTICAL COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CEREBROVASCULAR DISEASES - A pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol, and can be used to prepare the medicine for treating cerebrovascular diseases.||01-06-2011|
|20100210822||MODIFIED RECOMBINANT HUMAN ENDOSTATIN AND USES THEREOF - Provided is a kind of modified recombinant human endostatin that has the structure of CH||08-19-2010|
|20100160318||3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof - 3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.||06-24-2010|
Patent applications by Jiangsu Simcere Pharmaceutical R&D Co., Ltd.